Payment overview · 2025
General Payments
$3,230.83
80 reported records · 16 companies
Healthcare provider profile · identity verified
Bo Chen, M.D
Allopathic & Osteopathic Physicians|Internal Medicine · NEW YORK, NY · NPI 1356434104
Verified facts
What the public records show
CMS Open Payments records show Bo Chen, M.D received $3,230.83 in general payments during 2025 across 80 reported records.
Gilead Sciences, Inc. accounted for 38.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Gemtesa, Jardiance, Kerendia, Trelegy Ellipta, Vemlidy, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Linzess by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Nexium by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Jardiance by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 207 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trulicity by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $1,248.83 | 38.6% | 27 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $494.82 | 15.3% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $370.18 | 11.5% | 3 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $202.45 | 6.3% | 6 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $182.98 | 5.7% | 8 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $171.33 | 5.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $105.33 | 3.3% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $82.43 | 2.5% | 4 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $75.73 | 2.3% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $63.89 | 2.0% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $62.95 | 1.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $56.40 | 1.8% | 3 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $54.99 | 1.7% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.80 | 0.7% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $18.14 | 0.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.58 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,230.83 | 80 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $328.53 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $250.00 | 2 | 2025 |
Source payment records
|
|||||
| Livdelzi Normalized: livdelzi |
Drug | Gilead Sciences, Inc. | $249.26 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $202.45 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $201.11 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $187.76 | 9 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $182.98 | 8 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $171.33 | 2 | 2025 |
Source payment records
|
|||||
| Vemlidy Normalized: vemlidy |
Drug | Gilead Sciences, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $120.18 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $75.73 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $63.89 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $62.95 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $62.95 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $56.40 | 3 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $54.99 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $23.80 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $21.29 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $18.14 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 130 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 80 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 132 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Vemlidy vemlidy |
2025 | Vemlidy | 2024 | 207 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
130 | 26 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
79 | 15 |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
26 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
136 | 28 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
126 | 26 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
132 | 30 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
207 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
47 | 33 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
132 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
80 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1074 | 243 |
| Losartan Potassium | Losartan Potassium | 954 | 206 |
| Vascepa | Icosapent Ethyl | 598 | 121 |
| Raloxifene Hcl | Raloxifene Hcl | 590 | 109 |
| Simvastatin | Simvastatin | 524 | 117 |
| Amlodipine Besylate | Amlodipine Besylate | 471 | 96 |
| Diclofenac Epolamine | Diclofenac Epolamine | 429 | 90 |
| Omeprazole | Omeprazole | 406 | 98 |
| Metformin Hcl | Metformin Hcl | 398 | 77 |
| Meloxicam | Meloxicam | 375 | 135 |
| Tamsulosin Hcl | Tamsulosin Hcl | 340 | 72 |
| Metformin Hcl Er | Metformin Hcl | 305 | 63 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 286 | 107 |
| Meclizine Hcl | Meclizine Hcl | 281 | 84 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 270 | 69 |
| Fluticasone Propionate | Fluticasone Propionate | 263 | 77 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 246 | 100 |
| Allopurinol | Allopurinol | 233 | 64 |
| Vemlidy | Tenofovir Alafenamide | 207 | 25 |
| Trazodone Hcl | Trazodone Hcl | 205 | 74 |
| Ammonium Lactate | Ammonium Lactate | 181 | 74 |
| Hydrochlorothiazide | Hydrochlorothiazide | 164 | 35 |
| Alendronate Sodium | Alendronate Sodium | 163 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 139 | 30 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 138 | 45 |
| Farxiga | Dapagliflozin Propanediol | 136 | 28 |
| Glimepiride | Glimepiride | 135 | 25 |
| Clobetasol Propionate | Clobetasol Propionate | 134 | 41 |
| Januvia | Sitagliptin Phosphate | 134 | 23 |
| Jardiance | Empagliflozin | 132 | 30 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 131 | 28 |
| Lisinopril | Lisinopril | 131 | 27 |
| Creon | Lipase/Protease/Amylase | 130 | 26 |
| Nexium | Esomeprazole Magnesium | 126 | 26 |
| Fenofibrate | Fenofibrate,micronized | 123 | 25 |
| Levothyroxine Sodium | Levothyroxine Sodium | 122 | 21 |
| Atenolol | Atenolol | 120 | 28 |
| Procto-Med Hc | Hydrocortisone | 116 | 36 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 115 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 107 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 101 | 28 |
| Entecavir | Entecavir | 98 | 17 |
| Amoxicillin | Amoxicillin | 96 | 72 |
| Dexlansoprazole Dr | Dexlansoprazole | 96 | 27 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 89 | 25 |
| Donepezil Hcl Odt | Donepezil Hcl | 89 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 87 | 25 |
| Gemtesa | Vibegron | 80 | 22 |
| Hydrocortisone | Hydrocortisone | 80 | 25 |
| Linzess | Linaclotide | 79 | 15 |
| Montelukast Sodium | Montelukast Sodium | 79 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 76 | 31 |
| Finasteride | Finasteride | 75 | 16 |
| Halobetasol Propionate | Halobetasol Propionate | 75 | 26 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 73 | 60 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 72 | 19 |
| Mometasone Furoate | Mometasone Furoate | 71 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 65 | 19 |
| Tradjenta | Linagliptin | 59 | 12 |
| Azelastine Hcl | Azelastine Hcl | 56 | 21 |
| Cromolyn Sodium | Cromolyn Sodium | 55 | 24 |
| Loperamide | Loperamide Hcl | 54 | 32 |
| Trulance | Plecanatide | 50 | 11 |
| Celecoxib | Celecoxib | 48 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 48 | 11 |
| Xarelto | Rivaroxaban | 48 | suppressed |
| Mupirocin | Mupirocin | 47 | 11 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 47 | 33 |
| Gabapentin | Gabapentin | 46 | 13 |
| Icosapent Ethyl | Icosapent Ethyl | 46 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 42 | 12 |
| Myrbetriq | Mirabegron | 41 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 40 | 20 |
| Fluocinonide | Fluocinonide | 39 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 38 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 37 | suppressed |
| Eliquis | Apixaban | 36 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 36 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 35 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 33 | suppressed |
| Famotidine | Famotidine | 33 | suppressed |
| Furosemide | Furosemide | 31 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 29 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Prolia | Denosumab | 26 | 15 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 25 | 24 |
| Telmisartan | Telmisartan | 25 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 24 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 24 | 12 |
| Glipizide Er | Glipizide | 23 | suppressed |
| Ursodiol | Ursodiol | 23 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 22 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Lidocaine | Lidocaine | 21 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Acarbose | Acarbose | 20 | suppressed |
| Dutasteride | Dutasteride | 20 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Febuxostat | Febuxostat | 18 | suppressed |
| Silodosin | Silodosin | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Bepotastine Besilate | Bepotastine Besilate | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Kerendia | Finerenone | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Ciclopirox | Ciclopirox | 14 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 13 | suppressed |
| Restasis | Cyclosporine | 13 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Carvedilol | Carvedilol | 11 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Gabapentin Er | Gabapentin | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,230.83 · 80 records | Gilead Sciences, Inc. | AIRSUPRA, BREZTRI, CREON, Cologuard Collection Kit, EVENITY, Flucelvax, GEMTESA, IBSRELA, JARDIANCE, Kerendia, Livdelzi, OTEZLA, Ozempic, REPATHA, REZDIFFRA, Rybelsus, TRELEGY ELLIPTA, Vemlidy, ZENPEP, ZORYVE | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error